prednisone has been researched along with mitoxantrone in 313 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (3.19) | 18.7374 |
| 1990's | 88 (28.12) | 18.2507 |
| 2000's | 147 (46.96) | 29.6817 |
| 2010's | 64 (20.45) | 24.3611 |
| 2020's | 4 (1.28) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aversa, SM; Bianco, A; Chiarion-Sileni, V; Contu, A; Endrizzi, L; Fiorentino, MV; Olmeo, N; Salvagno, L; Schintu, GM; Sorarù, M | 1 |
| Higuchi, S; Itoh, T; Kishibe, T; Sakata, Y; Seino, Y; Sohma, N; Sugimoto, N; Suzuki, H | 1 |
| Mizoguchi, H; Saito, H | 1 |
| Cabanillas, F | 1 |
| Demina, EA; Evtushenko, VV; Kruglova, GV | 1 |
| Cabanillas, F; Fuller, L; Hagemeister, FB; McLaughlin, P; Rodriguez, M; Romaguera, J; Swan, F | 1 |
| Kimura, F; Mizukami, H; Motoyoshi, K; Nagata, N; Ohtsuki, T; Takagi, S; Takemura, Y; Yamamoto, K | 1 |
| Gimsing, P; Hedenus, M; Hippe, E; Palva, I; Talstad, I; Turesson, I; Westin, J; Wisløff, F | 1 |
| Cervantes, G; Corrado, C; Diaz Maqueo, JC; Erazo, A; Garcia Vela, EL; Lluesma Goñalons, M; Magnasco, H; Pavlovsky, S; Santarelli, MT; Somoza, N | 1 |
| Oguro, M; Sakai, C; Takagi, T | 1 |
| Gray, RG; Rees, JK | 1 |
| Björkholm, M; Ideström, K; Johansson, B; Kimby, E; Lindemalm, C; Merk, K; Osby, E | 1 |
| Bjerrum, OW; Brandt, E; Ellegaard, J; Evensen, SA; Gimsing, P; Hansen, MM; Hedenus, M; Hippe, E; Keldsen, N; Palva, I | 1 |
| Hagenbeek, A; Löwenberg, B; Michiels, J; Ruit, JB; Sizoo, W; Verhoef, GE; Wielenga, JJ | 1 |
| Cabanillas, F; Hagemeister, FB; Liang, JC; McLaughlin, P; Meistrich, ML; Redman, JR; Rodríguez, MA; Romaguera, JE; Swan, F; Velásquez, WS | 1 |
| Kühn, B; Löffler, H; Polchau, H; Rister, M; Suttorp, M | 1 |
| Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F | 1 |
| Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, T; Walters, R | 1 |
| Chen, PM; Chiou, TJ; Chiu, CF; Chuang, MW; Hsieh, RK; Liu, JH; Tzeng, CH | 1 |
| Cantinho-Lopes, MG; Carmo-Pereira, J; Costa, FO; Godinho, F; Henriques, E; Sales-Luis, A | 1 |
| Falkson, CI; Falkson, G; Terblanche, AP; Vorobiof, DA | 1 |
| Cuttner, J; Holland, JF; Keaveney, C; Paciucci, PA | 1 |
| Kimura, I; Masaoka, T; Namba, K; Ohnoshi, T; Sampi, K | 1 |
| Moser, K; Pohl, A | 1 |
| Hattori, M; Honda, T; Sampi, K | 1 |
| Cuttner, J; Holland, JF; Paciucci, PA | 1 |
| Lenzhofer, R; Rainer, H | 1 |
| Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H | 1 |
| Armitage, A; Coppin, C; Findlay, B; Moore, MJ; Murphy, K; Neville, A; Osoba, D; Tannock, IF; Venner, P; Wilson, J | 1 |
| Cabanillas, F; Hagemeister, FB; Lee, MS; McLaughlin, P; Pate, O; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Younes, A | 1 |
| Allen, PK; Besa, P; Cabanillas, F; Cox, JD; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, A; Swan, F | 1 |
| Baltali, E; Barista, I; Firat, D; Kansu, E; Karaağaoğlu, E; Kars, A; Ozisik, Y; Ruacan, S; Tekuzman, G; Uzunalimoğlu, B | 1 |
| Avilés, A; Díaz-Maqueo, JC; García, EL; Nambo, MJ; Talavera, A | 1 |
| Aasebø, U; Norum, J | 1 |
| Brandi, M; De Lena, M; Ditonno, P; Lorusso, V; Marzullo, F; Pellecchia, A; Timurian, A; Ventrella, V | 1 |
| Bendandi, M; Tura, S; Zinzani, PL | 1 |
| de Ridder, M; Hop, W; Lowenberg, B; Mulder, A; Nieuwenhuis, K; Schouten, H; Sonneveld, P; van der Lelie, H; van Reijswoud, I | 1 |
| Kelly, WK; Scher, HI; Steineck, G | 1 |
| Bezwoda, W; Diaz-Maqueo, JC; Erazo Valla, A; Moreno-Nogueira, JA; Morioka, H; Pavlovsky, S; Rastogi, RB; Resegotti, L; Rueckle, H; Somoza, N | 1 |
| Aster, JC; Inhorn, RC; Roach, SA; Slapak, CA; Soiffer, R; Stone, RM; Tantravahi, R | 1 |
| Hagemeister, FB | 1 |
| Bergmann, L; Hoelzer, D; Jacobi, V; Lob, S; Müller, H | 1 |
| Bailey, NM; Cabanillas, FF; Fuller, LM; Gabriel, GJ; Hagemeister, FB; Kattan, MW; Liang, JC; Wang, RY | 1 |
| Hayashi, K; Kawashima, K; Matsutomo, S; Mizuta, J; Ohnoshi, T; Saito, S; Tada, A; Tagawa, S; Ueno, K; Yoshino, T | 1 |
| Hainsworth, JD | 1 |
| Lichtman, SM | 1 |
| Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A | 1 |
| Adkins, DR; Dunphy, FR; Petruska, PJ; Spitzer, G; Velasquez, WS | 1 |
| Obrist, R | 1 |
| Bezwoda, W; Dreosti, LM; Gunter, K | 1 |
| Burkes, R; Chow, W; Crump, M; Davidson, M; Goss, PE; King, M; Myers, R; Poldre, P; Rudinskas, L; Sutton, D | 1 |
| Bezwoda, WR; Rastogi, RB | 1 |
| Herrmann, R; Hiddemann, W; Koch, P; Nahler, M; Unterhalt, M | 1 |
| Cabanillas, F; Fuller, L; Hagemeister, FB; McLaughlin, P; Purugganan, R; Rodriguez, M; Romaguera, J; Swan, F | 1 |
| Blijham, G; Hop, W; Michiels, JJ; Mulder, AH; Nieuwenhuis, K; Raemakers, JW; Sonneveld, P; van de Lelie, J; van der Heul, C | 1 |
| Cabanillas, F; Hagemeister, FB; Hess, M; McLaughlin, P; Podoloff, DA; Purugganan, R; Rodriguez, MA; Romaguera, JE; Swan, F | 1 |
| Bacovský, J; Faltýnek, L; Indrák, K; Papajík, T; Scudla, V | 1 |
| Carmo-Pereira, J; Costa, FO; Henriques, E | 1 |
| Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ | 1 |
| Gerrits, WB; Haak, HL; Kerkhofs, H; Wijermans, PW | 1 |
| Ansell, SM; Falkson, G | 1 |
| Chisesi, T | 1 |
| Burkes, R; Chow, W; Crump, M; Davidson, M; Goss, P; King, M; Myers, R; Poldre, P; Rudinskas, L; Sutton, D | 1 |
| Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
| Vogelzang, NJ | 1 |
| Armitage, GR; Coppin, CM; Ernst, DS; Moore, MJ; Murphy, KC; Neville, AJ; Osoba, D; Stockler, MR; Tannock, IF; Venner, PM; Wilson, JJ | 1 |
| Araki, K; Arima, N; Chiyoda, S; Hosokawa, T; Ikeda, S; Kawano, F; Kikuchi, H; Kinoshita, KI; Kohno, H; Matsuzaki, H; Miyoshi, I; Momita, S; Nishimura, H; Taguchi, H; Takahashi, H; Takatsuki, K; Tamura, K; Tomonaga, M; Tsuda, H; Uozumi, K; Yamada, O | 1 |
| Hatake, K; Imagawa, S; Izumi, T; Kuriki, K; Miura, Y; Muroi, K; Ogawa, Y; Ohtsuki, T; Ohya, K; Saito, K; Yoshida, M | 1 |
| Berman, E; Bertino, J; Feldman, E; Gee, T; Golde, D; Maslak, P; Megherian, L; Scheinberg, D; Seiter, K; Weiss, M | 1 |
| Nishikawa, K | 1 |
| Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Di Lollo, S; Ferrini, PR; Fusco, II; Innocenti, F; Longo, G; Rigacci, L; Stefanacci, S | 1 |
| Bierman, PJ; Galbraith, TA; Lackner, RP | 1 |
| Moore, MJ; Tannock, IF | 1 |
| Falkson, CI; Nel, JS | 1 |
| Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U | 1 |
| Bezwoda, WR; Dansey, R; Davidge-Pitts, M | 1 |
| Aitini, E; Bendandi, M; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Leone, G; Liso, V; Magagnoli, M; Moretti, L; Pavone, E; Storti, S; Tabanelli, M; Tura, S; Venturi, S; Zinzani, PL | 1 |
| Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL | 1 |
| Cabanillas, FF; Fuller, LM; Ha, CS; Hagemeister, FB; Lipshultz, LI; Mathur, K; McLaughlin, P; Meistrich, ML; Rodriguez, MA; Romaguera, JE; Wilson, G | 1 |
| Bron, D; Errante, D; Kluin-Nelemans, JC; Noordijk, EM; Rosti, G; Somers, R; Teodorovic, I; Thomas, J; Tirelli, U; Van Glabbeke, M; Zagonel, V | 1 |
| Corey, P; Goodwin, P; Osoba, D; Stockler, MR; Tannock, IF | 1 |
| Busch, M; Freund, M; Hanrath, RD; Helm, G; Herrmann, R; Hiddemann, W; Kaiser, U; Kreuser, ED; Middeke, H; Neubauer, A; Parwaresch, R; Reuss-Borst, M; Stein, H; Terhardt-Kasten, E; Tiemann, M; Trümper, L; Unterhalt, M; Wöltjen, HH | 1 |
| Bairey, O; Blickstein, D; Epstein, O; Gabbay, U; Lahav, J; Prokocimer, M; Shaklai, M; Stark, P | 1 |
| Bloomfield, DJ; Ernst, S; Krahn, MD; Moore, MJ; Neogi, T; Neville, A; Panzarella, T; Smith, TJ; Tannock, IF; Warde, P; Willan, AR | 1 |
| Ariyoshi, K; Kameda, N; Shinohara, K; Takeda, K | 1 |
| Colomer, R; Gómez, H | 1 |
| Cabanillas, F; Dong, K; Hagemeister, FB; McLaughlin, P; Moon, T; Rodriguez, MA; Rodriguez-Diaz Pavón, J; Romaguera, JE | 1 |
| Campo, E; Cervantes, F; Esteve, J; Montserrat, E; Rafel, M; Serra, A; Velasco, M | 1 |
| Astori, C; Bernasconi, C; Bernasconi, P; Lazzarino, M; Orlandi, E | 1 |
| Boerman, RH; Mattijssen, V; Mulder, AH; Raemaekers, JM | 1 |
| Bremnes, RM; Bremnes, Y; Dønnem, T | 1 |
| Cabanillas, F; Fayad, L; Hagemeister, FB; Hess, M; McLaughlin, P; Rodriguez, J; Rodriguez, MA; Romaguera, J; Santiago, M | 1 |
| Benet, I; Garcia-Conde, J; Marugán, I; Solano, C; Terol, MJ; Tormo, M | 1 |
| Aitini, E; Bendandi, M; Bocchia, M; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Leone, G; Magagnoli, M; Mazza, P; Moretti, L; Pavone, E; Storti, S; Tabanelli, M; Tura, S; Volpe, E; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Corey, P; Goodwin, PJ; Osoba, D; Stockler, MR; Tannock, IF | 1 |
| Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Cox, JD; Dubey, P; Fuller, LM; Ha, CS; Hagemeister, FB; Mathur, KK; Meistrich, ML; Wilson, G | 1 |
| Czaykowski, PM; Dowling, AJ; Krahn, MD; Moore, MJ; Tannock, IF | 1 |
| Bouabdallah, R; Cole, BF; Gisselbrecht, C; Haioun, C; Lepage, E; Marit, G; Morel, P; Mounier, N; Ravoet, C; Reyes, F; Salles, G; Sebban, C | 1 |
| Haas, R; Ho, AD; Hohaus, S; Martin, S; Moos, M; Pantel, G; Schmidt, P; Voso, MT; Weis, M | 1 |
| Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M | 1 |
| Kraszewska, E; Krzyzanowska, JB; Lampka, E; Meder, J; Miśkiewicz, Z; Romejko-Jarosińska, J; Walewski, J | 1 |
| Allen, PK; Choe, JG; Cox, JD; Edmund, E; Ha, CS; Kong, JS; Oh, YK | 1 |
| Balaguer-Martínez, JV; Castillo-Pallarés, FJ; Ferrer Albiach, C; Pallardó-Calatayud, J; Romero-de-Avila, C; Ruiz Hernández, G | 1 |
| Weiss, M | 1 |
| Erdkamp, FL; Fickers, MM; Houben, SG; Lalisang, RI; Peters, FP; Schouten, HC; Wals, J; Wils, JA | 1 |
| Chisesi, T; Congiu, AM; Contu, A; Coser, P; Indrizzi, L; Leoni, P; Majolino, I; Polistena, P; Porcellini, A; Rizzoli, V; Salvagno, L; Santini, G; Zambaldi, G | 1 |
| Lin, DY; Willan, AR | 1 |
| Cabanillas, FF; Cox, JD; Ha, CS; Hess, MA; Rodriguez, MA; Tucker, SL; Wilder, RB | 1 |
| Fletcher, BD; Harrison, PL; Kaste, SC; Kennedy, W; Neel, MD; Pui, CH; Razzouk, BI; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT | 1 |
| Allen, SL; Budman, DR; Fusco, D; Hayes, FA; Hoffman, M; Kolitz, J; Lichtman, SM; Mittelman, A; Schulman, P; Vinciguerra, V | 1 |
| Dowling, AJ; Ernst, DS; Moore, MJ; Neville, AJ; Panzarella, T; Tannock, IF | 1 |
| Burnett, AK; Clark, RE; Goldstone, AH; Hutchinson, RM; Smith, AG; Wheatley, K | 1 |
| Zivin, JG | 1 |
| Knox, JJ; Moore, MJ | 1 |
| Beer, TM; Bubalo, JS | 1 |
| Carter, WB; Delgado, DJ; Ford, JM; Fridman, M; Kerr, RO; Lawless, GD; Lee, MW; Morrison, VA; Picozzi, VJ; Pohlman, BL | 1 |
| Bollas, G; Dervenoulas, J; Economopoulos, T; Kalantzis, D; Koumarianou, A; Mantzios, G; Papageorgiou, E; Raptis, S; Rontogianni, D; Tsirigotis, P | 1 |
| Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K | 1 |
| Bordessoule, D; Bosly, A; Coiffier, B; Deconninck, E; Divine, M; Dupriez, B; Fillet, G; Gaulard, P; Gisselbrecht, C; Herbrecht, R; Lepage, E; Nouvel, C; Tilly, H | 1 |
| Barista, I; Cabanillas, F; Chronowski, GM; Cox, JD; Ha, CS; Hagemeister, FB; Jones, D; Schlembach, PJ; Wilder, RB; Younes, A | 1 |
| Armitage, JO | 1 |
| Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Mellou, S; Nicolaides, C; Papadopoulos, A; Papageogriou, E; Papasavvas, P; Pavlidis, N; Samantas, E; Tsatalas, C | 1 |
| Chisesi, T; Deliliers, GL; Federico, M; Gobbi, PG; Levis, A; Linfomi, MB; Luminari, S; Santini, G | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Aoun, P; Armitage, JO; Bast, M; Bierman, PJ; Bociek, G; Chan, JC; Greiner, T; Lynch, JC; Vose, JM; Weisenburger, DD | 1 |
| Aitini, E; Alinari, L; Baccarani, M; Ciccone, F; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Lauria, F; Lauta, VM; Mannina, D; Mazza, P; Moretti, L; Pavone, E; Stefoni, V; Storti, S; Tani, M; Tura, S; Volpe, E; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E | 1 |
| Büchler, T; Ferra, C; Grañena, A; Montanya, E; Virgili, N | 1 |
| Boński, JZ; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Hellmann, A; Kasznicki, M; Konopka, L; Robak, T; Wołowiec, D | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD | 1 |
| Asmar, L; Berry, W; Dakhil, S; Gregurich, M; Modiano, M | 1 |
| Kelly, WK; Scher, HI | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Bosi, A; Carpaneto, A; Carrai, V; Longo, G; Rigacci, L; Rossi Ferrini, P | 1 |
| Bishop, JB; Frias, S; Hagemeister, FB; Lowe, XR; Meistrich, ML; Shelby, MD; Van Hummelen, P; Wyrobek, AJ | 1 |
| Anderson, H; Björkholm, M; Cavallin-Stahl, E; Hagberg, H; Holte, H; Kvaløy, S; Myhre, J; Osby, E; Pertovaara, H; Teerenhovi, L | 1 |
| Bessell, EM; Burton, A; Child, JA; Cullen, MH; Davies, JM; Ellis, IO; Glaholm, J; Haynes, AP; Jack, A; Jones, EL; Smith, GM | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Abebe, L; Adiga, GU; Wiernik, PH | 1 |
| Beer, TM; Bubley, G; Dalton, WS; Einstein, A; Ette, E; Garg, V; Harding, MW; Henner, WD; Ko, YJ; Lush, R; Merica, EA; Rago, RP | 1 |
| Angelopoulou, MK; Bourantas, KL; Christopoulos, G; Grigorakis, V; Kalmantis, T; Kokkinis, G; Korantzis, J; Michalis, E; Mihalakeas, I; Pangalis, GA; Papayiannis, A; Repousis, P; Roussou, P; Siakantaris, MP; Stamatellou, M; Stefanoudakis, E; Symeonidis, A; Vassilakopoulos, TP; Vrakidou, E | 1 |
| Greco, FA; Hainsworth, JD; Lamb, MR; Litchy, S; Rodriguez, GI; Scroggin, C | 1 |
| Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Vianelli, N; Zinzani, PL | 1 |
| Delgado, DJ; Lyman, GH | 1 |
| Atkinson, EN; Barista, I; Cabanillas, F; Chronowski, GM; Cox, JD; Ha, CS; Hagemeister, FB; Hess, MA; Levy, LB; Rodriguez, MA; Sarris, AH; Wilder, RB | 1 |
| Bernardi, D; Simonelli, C; Spina, M; Talamini, R; Tirelli, U; Vaccher, E; Zanetti, M | 1 |
| Kitanishi, T; Kitano, H; Kouzaki, H; Suzuki, M | 1 |
| Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP | 1 |
| Canil, CM; Tannock, IF | 1 |
| Askling, J; Björkholm, M; Dickman, PW; Ekbom, A; Landgren, O; Osby, E | 1 |
| Heine, K; Wolff, JM | 1 |
| Abrams, J; Al-Katib, A; Ibrahim, D; Karanes, C; Lai, P; Millenson, M; Pemberton, P; Smith, MR; Varterasian, M; Yeslow, G | 1 |
| Crawford, J; Dale, DC; Fisher, RI; Friedberg, J; Lyman, GH | 1 |
| Berry, WR; Chi, KN; de Wit, R; Eisenberger, MA; Horti, J; James, ND; Oudard, S; Pluzanska, A; Rosenthal, MA; Tannock, IF; Théodore, C; Turesson, I | 1 |
| Benson, MC; Berry, D; Burch, PA; Crawford, ED; Hussain, MH; Jones, JA; Kohli, M; Lara, PN; Moinpour, C; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME | 1 |
| Konski, A | 1 |
| Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R | 1 |
| Areal, J; Arroyo, FR; Constenla, M; Font, A; Martin, C; Murias, A; Rosell, R; Saladie, JM; Sanchez, JJ; Santiago, JA | 1 |
| Fujino, H; Hayashi, K; Hirai, M; Hirose, A; Ishii, K; Katsurada, T; Kitajima, H; Kitayama, H; Mugitani, A; Ohta, T; Shigeki, T; Teshima, H; Urase, F; Yagi, T; Yamamoto, Y | 1 |
| Berthou, C; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Desablens, B; Foussard, C; Ghandour, C; Gressin, R; Lamy, T; Mahé, B; Maisonneuve, H; Pignon, B; Rachieru, P; Rousselet, MC | 1 |
| Itoh, N | 1 |
| de Wit, R | 1 |
| Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E | 1 |
| Drage, NA; Howarth, A; Wickramasinghe, A | 1 |
| Van Poppel, H | 1 |
| Kluin, PM; Kluin-Nelemans, HC; Kramer, MH; MacKenzie, MA; Meulendijks, LA; Ossenkoppele, GJ; Raemaekers, JM; Schouten, HC; Sonneveld, P; van 't Veer, MB; van der Holt, B; van Imhoff, GW; van Marwijk Kooy, M; van Oers, MH; Verdonck, LF; Wijermans, PW | 1 |
| Kluin, PM; Kluin-Nelemans, HC; Mackenzie, MA; Ossenkoppele, GJ; Schouten, HC; Sonneveld, P; Steijaert, MM; van der Holt, B; van Imhoff, GW; Van't Veer, MB; Verdonck, LF; Wijermans, PW | 1 |
| George, DJ; Moore, CN | 1 |
| Ferrero, JM | 1 |
| Doggrell, SA | 1 |
| Berry, WR | 1 |
| Petrylak, DP | 2 |
| Kibel, AS | 1 |
| Angelucci, E; Baldini, L; Boccomini, C; Brugiatelli, M; Cabras, MG; Calvi, R; Ciccone, G; Deliliers, GL; Federico, M; Gallo, E; Genua, A; Levis, A; Liberati, AM; Parvis, G; Pavone, E; Salvi, F; Sborgia, M; Vitolo, U | 1 |
| Chamorey, E; Delwail, V; Fabbro, M; Foussard, C; Gressin, R; Harrousseau, JL; Lepeu, G; Maisonneuve, H; Peyrade, F; Richard, B; Rossi, JF; Thyss, A; Vilque, JP | 1 |
| Cabanillas, F; Cox, JD; Ha, CS; Lee, MS; McLaughlin, P; Mesina, OM; Rodriguez, MA; Romaguera, JE; Tucker, SL; Younes, A | 1 |
| Enschede, SH; Gregory, SA; Porter, C; Venugopal, P | 1 |
| Brandes, LJ; Klapp, K; Lieskovsky, G; Quinn, DI; Raghavan, D; Ramsey, EW; Snyder, T; Styles, E; Tsao-Wei, D | 1 |
| Protheroe, A | 1 |
| Sleijfer, S; Stoter, G | 1 |
| Bartsch, R; Drach, J; Hejna, M; Raderer, M; Wöhrer, S | 1 |
| Burton, C; Cunningham, D; Dyer, MJ; Hancock, B; Hoskin, P; Jack, A; Linch, D; MacLennan, K; Milligan, D; Mouncey, P; Qian, W; Smith, P; Webb, A | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME | 1 |
| Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T | 1 |
| Kageyama, Y; Kihara, K; Kobayashi, T; Kubo, Y; Yokoyama, M | 1 |
| Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV | 1 |
| Chang, SS; Rumohr, JA | 1 |
| Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Chott, A; Drach, J; Jager, U; Puspok, A; Raderer, M; Streubel, B; Troch, M; Turetschek, K; Wohrer, S; Zielinski, CC | 1 |
| Inamura, K; Kakuta, K; Matano, S; Munemoto, S; Nishijima, H; Okamura, T; Satoh, S; Sugimoto, T | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Marcus, R | 1 |
| Bakshi, A; Gujral, S; Gupta, S; Nair, R; Parikh, P; Prabhash, K; Sengar, M | 1 |
| Aspillaga, A; Cabrera, ME; Cerda, B; García, H; Hales, C; León, A; Lois, V; Meneses, P; Merino, C; Oliva, J; Peña, K; Rojas, H; Rosas, J; Rossle, A; Vittini de, C | 1 |
| Gross, M; Hussain, MH; Hutcheon, D; Kelly, WK; Michaelson, D; Rosenberg, JE; Small, EJ; Weinberg, VK; Wilding, G | 1 |
| Fukao, M; Isogai, R; Kawada, A | 1 |
| Armstrong, AJ; Carducci, MA; de Wit, R; Eisenberger, M; Garrett-Mayer, E; Ou Yang, YC; Tannock, I | 1 |
| Bladou, F; Gravis, G; Salem, N; Viens, P | 1 |
| Morrison, VA | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; Garrett-Mayer, ES; Tannock, IF; Yang, YC | 1 |
| Aguila, B; Allouche, S; Balboni, G; Borsodi, A; Boulouard, M; Coulbault, L; Davis, A; Jauzac, P; Léveillé, F; Salvadori, S; Tóth, G | 1 |
| Alinari, L; Baccarani, M; Bacci, F; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Dai, B; Shen, YJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhang, W; Zhu, Y | 1 |
| Aitini, E; Andreuccetti, M; Antonuzzo, A; Barbieri, R; Di Marsico, R; Falcone, A; Fontana, A; Fontana, E; Galli, C; Galli, L; Landi, L | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Burzykowski, T; Buyse, M; Collette, L | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Soban, F; Tannock, IF | 1 |
| Ahlbom, A; Anders, A; Andersson, T; Björkholm, M; Eva, O; Magnus, B; Ösby, E; Tomas, A | 1 |
| Crawford, ED; Flaig, TW; Glodé, LM; Hussain, MH; Raghavan, D; Stadler, WM; Tangen, CM | 1 |
| Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R | 1 |
| Armstrong, AJ; Eisenberger, M; Garrett-Mayer, EL | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Roessner, M; Tannock, AI | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Tannock, IF | 1 |
| Aversa, SML; Bianco, A; Errante, D; Salvagno, L | 1 |
| Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; Halabi, S; Tannock, IF | 1 |
| Birkmann, J; Bodenstein, H; Clemens, M; Fuchs, R; Hänel, M; Hensel, M; Peter, N; Pfreundschuh, M; Reiser, M; Zeynalova, S; Ziepert, M; Zwick, C | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Choi, WW; Fu, K; Greiner, TC; Hans, CP; Perry, KD; Shi, X; Smith, LM; Vose, JM; Weisenburger, DD | 1 |
| Haines, IE; Stanley, RM | 1 |
| Beer, TM; Chan, JS; Dehaze, DR; Garzotto, M; Pinski, JK; Quinn, DI; Ryan, CW; Sokoloff, M | 1 |
| Beverloo, HB; Cornelissen, JJ; Deenik, W; Valk, PJ; van der Poel-van de Luytgaarde, SC; van Esser, JW; Wattel, MM | 1 |
| Jonathan, F | 1 |
| Donaldson, GW; Moinpour, CM; Nakamura, Y | 1 |
| Angrilli, F; Baldini, L; Bari, A; Ilariucci, F; Lazzaro, A; Luminari, S; Marcheselli, L; Pozzi, S; Sacchi, S; Stelitano, C | 1 |
| Li, Y; Mi, Y; Qiu, L; Wang, J; Zhao, Y; Zou, D | 1 |
| Held, G; Pfreundschuh, M | 1 |
| Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G | 1 |
| Clarke, SJ; Cunningham, D; Dent, O; Robertson, G; Sharma, R; Smith, P | 1 |
| Janikova, A; Koristek, Z; Kral, Z; Mayer, J; Navratil, M; Pavlik, T; Sticha, M; Vasova, I; Vinklarkova, J | 1 |
| Gao, J; Ma, HH; Ma, J; Pan, HF; Qian, LT; Wang, ZH; Wu, AD; Yang, L; Zhang, HY; Zhao, YF | 1 |
| Batteux, F; Debray, M; Hirt, D; Laurent, A; Pavlovic, S; Poupon, J; Richardet, JP; Sogni, P; Treluyer, JM; Urien, S; Weill, B | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; George, DJ; Halabi, S; Tannock, IF | 1 |
| Beaumont, J; Cella, D; Eton, DT; Shevrin, DH; Victorson, D | 1 |
| Brodsky, EM; Daters, AT; Mauldin, GE; Mauldin, GN; Post, GS | 1 |
| Gill, D; Ho, AD; Kuhnt, E; Loeffler, M; Österborg, A; Pettengell, R; Pfreundschuh, M; Rieger, M; Walewski, J; White, D | 1 |
| Dorff, TB; Quinn, DI | 1 |
| Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L | 1 |
| Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Miura, Y; Naito, Y; Shigeta, K; Takano, T | 1 |
| Oudard, S | 1 |
| Agostinelli, C; Broccoli, A; Faccioli, L; Pastore Trossello, M; Spinardi, L; Stefoni, V; Zinzani, PL | 1 |
| Berry, S; Chi, K; Czaykowski, P; Eigl, B; Gleave, M; Hotte, S; Lattouf, JB; Mukherjee, SD; North, S; Pollak, M; Saad, F; Winquist, E; Wood, L | 1 |
| Andersson, PO; Hansson, U; Hasselblom, S; Lewerin, C; Nilsson-Ehle, H; Sender, M; Stenson, M; Werlenius, O | 1 |
| Bozzoli, V; D'Aló, F; Giachelia, M; Hohaus, S; Larocca, LM; Leone, G; Martini, M; Massini, G; Tisi, MC; Voso, MT | 1 |
| Kawaguchi, K; Kinebuchi, Y; Suzuki, A; Tsuruta, T; Wajiki, M | 1 |
| Bandekar, R; Cornfeld, M; Davis, NB; De Bono, JS; Fizazi, K; Flechon, A; Heidenreich, A; Hudes, GR; Qi, M; Vermeulen, JT; Voog, E | 1 |
| Asmar, L; Awasthi, S; Beer, TM; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Kolodziej, M; Martincic, D; Rastogi, A; Rauch, MA; Rousey, SR; Sonpavde, G; Wang, Y; Weinstein, RE | 1 |
| Bian, XJ; Dai, B; Shen, YJ; Xie, HY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y | 1 |
| Buckley Woods, H; Papaioannou, D; Rafia, R; Rathbone, J; Stevens, J; Stevenson, M | 1 |
| Alumkal, J; Dubey, S; Fizazi, K; Forget, F; Gerritsen, WR; Gravis, G; Jiang, Y; Loh, E; Machiels, JP; Ng, S; Oliner, KS; Picus, J; Rosenthal, M; Ryan, CJ; Srinivas, S; Tang, R; Zhu, M | 1 |
| Angrilli, F; Arcaini, L; Brugiatelli, M; Carella, AM; Dell'olio, M; Di Raimondo, F; Dondi, A; Federico, M; Franco, V; Gaidano, G; Galimberti, S; Luminari, S; Marcheselli, L; Merli, F; Pulsoni, A; Rigacci, L; Sacchi, S; Stelitano, C; Tucci, A; Vitolo, U | 1 |
| Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O | 1 |
| Cantor, R; Demeure, O; Eskin, E; Ghazalpour, A; Hormozdiari, F; Lagarrigue, S; Lusis, AJ; Martin, L; Pan, C; Roux, PF; van Nas, A | 1 |
| Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Cunningham, D; Linch, DC; Lowry, L; Smith, P | 1 |
| Armstrong, AJ; de Bono, J; Halabi, S; Kaplan, EB; Lin, CY; Oudard, S; Petrylak, D; Sartor, O; Shen, L; Small, EJ; Sternberg, CN | 1 |
| Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L | 1 |
| Bergsagel, J; Cooper, T; Daves, M; Keller, F; Lew, G; Nickel, RS; Sabnis, H | 1 |
| Broccoli, A; Casadei, B; Derenzini, E; Gandolfi, L; Pellegrini, C; Zinzani, PL | 1 |
| Fujiwara, K; Fukuhara, T; Kitano, H; Okazaki, T | 1 |
| Chen, SP; Huang, YR; Jie, J; Na, YQ; Sun, Y; Sun, YH; Tian, Y; Wei, Q; Xie, LP; Yang, Y; Yao, X; Ye, DW; Ye, ZQ; Zeng, SX; Zhang, W; Zhang, X; Zhou, FJ; Zhou, T | 1 |
| Ndibe, C; Sonpavde, G; Wang, CG | 1 |
| Alvarez, I; Anastasia, A; Arcari, A; Bari, A; Botto, B; Carella, AM; Chiarenza, A; Dondi, A; Federico, M; Marcheselli, L; Puccini, B; Salvi, F | 1 |
| Basch, E; Corty, RW; Dusetzina, SB; Green, AK; Meeneghan, M; Milowsky, MI; Reeder-Hayes, KE; Wood, WA | 1 |
| Armstrong, A; Ferrari, A; Hainsworth, J; Higano, CS; Hozak, RR; Hussain, M; Joshi, A; Kelly, WK; Liu, G; Rathkopf, D; Schwartz, JD; Yang, L | 1 |
| Feng, X; Gu, Z; Li, F; Li, Z; Liu, W; Qi, J; Qiu, L; Xu, Y; Yi, S; Yu, Z; Zhan, F; Zou, D | 1 |
| Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J | 1 |
| de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S | 1 |
| Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X | 1 |
| Lee, JJ; Liao, AT; Wang, SL | 1 |
| Butte, AJ; Geifman, N | 1 |
| Guo, C; He, P; Sun, C; Wang, X; Zhang, M | 1 |
| Abdallah, K; Bates, SE; Beetsch, J; Curt, G; Fojo, T; Hugh-Jones, C; Lebowitz, P; Morrell, J; Murphy, M; Rothenberg, M; Sargent, DJ; Scher, HI; Simantov, R; Simon, R; Stein, WD; Wilkerson, J | 1 |
| Angelucci, E; Angrilli, F; Arcaini, L; Bertoldero, G; Cascavilla, N; Chiarenza, A; Dondi, A; Federico, M; Ferrari, A; Ferreri, AJM; Gaidano, G; Kovalchuk, S; Luminari, S; Manni, M; Marcheselli, L; Merli, F; Pulsoni, A; Rusconi, C; Salvi, F; Stelitano, C; Tarantino, V; Tucci, A; Vallisa, D; Vitolo, U | 1 |
| Bocchia, M; Cencini, E; Fabbri, A; Gentili, F; Mazzei, MA; Schiattone, L | 1 |
| Crawford, ED; Dawson, NA; Dorff, TB; Flaig, TW; Glode, LM; Haas, NB; Hussain, M; Lin, DW; Quinn, DI; Sakr, W; Swanson, GP; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wood, DP | 1 |
| Sartor, O | 1 |
| Borel, P; Buffière, C; Caris-Veyrat, C; Goupy, P; Halimi, C; Margier, M; Reboul, E; Remond, D | 1 |
| Gourd, E | 1 |
| Huang, C; Song, P; Wang, Y | 1 |
| Ma, Y; Newton, PK; West, J | 1 |
| Dams, J; Dobruschkin, A; Grochtdreis, T; König, HH; von Amsberg, G | 1 |
| Antonarakis, ES; Basch, EM; Bennett, AV; Chi, KN; Dayan, E; de Bono, JS; de Souza, P; Dreicer, R; Dueck, AC; George, S; Holland, J; Hutson, TE; Kalebasty, AR; Mangeshkar, M; Marx, G; O'Sullivan, JM; Scher, HI; Scholz, M; Schwarz, JK; Vaishampayan, U; Vogelzang, N; Weitzman, AL | 1 |
| Ali, T; Caffo, O; Castellano, D; Demkow, T; Hakenberg, OW; Heidenreich, A; Ilaria, R; Nippgen, J; Novosiadly, RD; Pavlik, I; Perez-Gracia, JL; Qin, A; Sautois, B; Schultze-Seemann, W; Shahir, A | 1 |
| Araujo, JC; Chi, KN; De Bono, JS; Dutta, S; Eisenberger, MA; Fizazi, K; George, DJ; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Morris, MJ; Petrylak, DP; Quinn, DI; Rosenthal, M; Small, EJ; Tangen, CM; Tannock, IF; Thompson, IM | 1 |
| Cannon, CM; Childress, MO; Lindley, SES; Marquardt, TM; Northrup, NC; Rodriguez, CO; Smith, AN; Thamm, DH | 1 |
| Fukui, T; Goto, M; Hakiri, S; Hashimoto, K; Ito, T; Kawaguchi, K; Mori, S; Nakamura, S; Ozeki, N; Yokoi, K | 1 |
| Budau, L; Burchert, A; Dölken, G; Herold, M; Hirt, C; Jäkel, J; Maschmeyer, G; Moll, R; Neubauer, A; Neubauer, E; Strauch, K; Wilhelm, C | 1 |
| Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H | 1 |
| Chen, M; Chen, X; Fang, F; Guo, J; Han, L; Hung, MC; Kuang, X; Li, H; Li, J; Liang, L; Liu, H; Liu, J; Ma, F; Peng, C; Su, J; Sun, L; Tao, J; Weng, L; Xie, Y; Xie, Z; Xu, X; Yang, N; Ye, Y; Zhang, J; Zhang, X; Zhang, Y; Zhao, S | 1 |
| Aramaki, K; Ikeda, N; Kosono, S; Shiozaki, Y | 1 |
| Liu, Y; Wang, S; Ye, H; Zhang, L; Zhou, Y | 1 |
| Frias, S; Meistrich, ML; Van Hummelen, P; Wyrobek, AJ | 1 |
44 review(s) available for prednisone and mitoxantrone
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Recent developments in chemotherapy of malignant diseases].
Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Female; Genetic Techniques; Hodgkin Disease; Hormones; Humans; Immunotherapy; Interferons; Male; Mechlorethamine; Methotrexate; Mitoxantrone; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nitrosourea Compounds; Osteosarcoma; Prednisone; Procarbazine; Prognosis; Receptors, Cell Surface; Tretinoin; Vincristine | 1982 |
Hormone-refractory (D3) prostate cancer: refining the concept.
Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Humans; Hydrocortisone; Male; Medroxyprogesterone; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Suramin; Treatment Outcome | 1995 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Eosinophilia; Etoposide; Fatal Outcome; Female; Humans; Hydroxyurea; Hyperplasia; Ifosfamide; Leukemia, Myeloid; Lymph Nodes; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Syndrome; Translocation, Genetic; Vincristine | 1995 |
The use of mitoxantrone in the treatment of breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Mitoxantrone; Prednisone; Quality of Life | 1995 |
Lymphoma in the older patient.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lymphoma; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Quality of Life; Risk Factors; Survival Analysis; Thiotepa; Vincristine | 1995 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies | 1994 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine | 1996 |
Overview of Canadian trials in hormonally resistant prostate cancer.
Topics: Antineoplastic Agents; Canada; Clinical Trials as Topic; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life | 1996 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Palliative Care; Prednimustine; Prednisolone; Prednisone; Prognosis; Vincristine | 1998 |
[Primary MALT-type lymphoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Vincristine | 1998 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Dactinomycin; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Male; Mitoxantrone; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Suramin | 2001 |
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Gastrointestinal Diseases; Humans; Male; Mitoxantrone; Nervous System Diseases; Paclitaxel; Prednisone; Prostatic Neoplasms; Taxoids | 2001 |
The role of mitoxantrone in non-Hodgkin's lymphoma.
Topics: Age Factors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Mitoxantrone; Prednisolone; Prednisone; Salvage Therapy; Vincristine | 2002 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Survival Rate; Treatment Outcome | 2003 |
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Female; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lomustine; Male; Middle Aged; Mitoxantrone; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Prednisone; Prognosis; Reed-Sternberg Cells; Remission Induction; Skin Neoplasms; Splenectomy; Tumor Virus Infections; Vidarabine; Vinblastine; Vincristine | 2003 |
Is there a role for chemotherapy in prostate cancer?
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Estramustine; Estrogens; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Taxoids | 2004 |
[Chemotherapy of the hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisone; Prostatic Neoplasms; Taxoids | 2004 |
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compounds; Docetaxel; Drug Resistance; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2005 |
Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; Estramustine; Humans; Male; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Which drug combination for hormone-refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2005 |
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Future directions in the treatment of androgen-independent prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Estramustine; Forecasting; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
An interdisciplinary approach to treating prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tosyl Compounds | 2005 |
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2006 |
Use of rituximab in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Follicular; Mitoxantrone; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Rituximab; Vincristine | 2007 |
[Prostate cancer and chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Longitudinal Studies; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prevalence; Prognosis; Recombinant Proteins; Survival Rate; Teniposide; Vincristine | 2007 |
CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisolone; Prednisone; Treatment Outcome; Vincristine | 2008 |
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Erdheim-Chester Disease; Etoposide; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitoxantrone; Prednisone; Treatment Outcome; Vincristine | 2012 |
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; England; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Models, Economic; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Rituximab; Vincristine; Wales | 2012 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Corticosteroids in the management of prostate cancer: a critical review.
Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2016 |
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Network Meta-Analysis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Topics: Aged; Antineoplastic Agents; Bias; Cost-Benefit Analysis; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Tissue Extracts | 2018 |
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; White People | 2019 |
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine | 2019 |
132 trial(s) available for prednisone and mitoxantrone
| Article | Year |
|---|---|
NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Tolerance; Hodgkin Disease; Humans; Mitoxantrone; Neoplasm Staging; Prednisone; Radiotherapy Dosage; Remission Induction; Time Factors; Vinblastine; Vincristine | 1992 |
Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Resistance; Female; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Vincristine | 1992 |
Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Vincristine | 1992 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Vincristine | 1991 |
[A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Vincristine | 1986 |
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisone; Vincristine | 1984 |
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Humans; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires | 1994 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Neoplasm Staging; Oncogenes; Polymerase Chain Reaction; Prednisone; Procarbazine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Remission Induction; Treatment Outcome; Vincristine | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vincristine | 1994 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Karnofsky Performance Status; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Treatment Failure; Vincristine | 1995 |
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine | 1995 |
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cyclophosphamide; Doxorubicin; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Nausea; Prednisolone; Prednisone; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Vincristine; Vomiting | 1995 |
Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Survival Analysis; Treatment Failure; Vincristine | 1995 |
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies | 1994 |
A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Mitoxantrone; Prednisolone; Prednisone; Vincristine | 1994 |
New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphom
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Germany; Humans; Interferon-alpha; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Prednimustine; Prednisone; Vincristine | 1994 |
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Prednisone; Prospective Studies; Vincristine | 1994 |
Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Prospective Studies; Thrombocytopenia; Time Factors | 1993 |
Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Teniposide; Vincristine | 1993 |
A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Remission Induction | 1993 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neoplasm Staging; Prednisone | 1995 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Orchiectomy; Pain; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate | 1996 |
An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Prednisone; Vincristine; Vindesine | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Prednisone; Treatment Outcome; Vincristine | 1997 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine | 1997 |
Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans; Male; Mitoxantrone; Prednisone; Sperm Count; Spermatogenesis; Time Factors; Vinblastine; Vincristine | 1997 |
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednimustine; Prednisone; Vincristine | 1998 |
Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. Europea
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Canada; Humans; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Psychometrics; Quality of Life; Surveys and Questionnaires | 1998 |
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednimustine; Prednisone; Prospective Studies; Survival Rate; Vincristine | 1998 |
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.
Topics: Canada; Cost-Benefit Analysis; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 1998 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Vincristine | 1998 |
Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Vinblastine; Vincristine | 1999 |
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Vincristine | 1999 |
Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cross-Sectional Studies; Discriminant Analysis; Humans; Linear Models; Male; Middle Aged; Mitoxantrone; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Sickness Impact Profile; Surveys and Questionnaires | 1999 |
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cross-Over Studies; Disease Progression; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 1999 |
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Multivariate Analysis; Prednisone; Quality of Life; Survival Analysis; Transplantation, Autologous; Vindesine | 2000 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; L-Lactate Dehydrogenase; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prednisone; Prognosis; Safety; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vincristine | 2000 |
Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Citrates; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Gallium; Gallium Radioisotopes; Hodgkin Disease; Humans; Lymphography; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vincristine | 2000 |
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
Topics: Actuarial Analysis; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Survival Rate; Treatment Outcome | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Retrospective Studies; Salvage Therapy; Vincristine | 2001 |
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Thiotepa; Vincristine | 2001 |
A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Cross-Over Studies; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Survival Rate; Time Factors; Vincristine | 2002 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Treatment Outcome; Vinblastine; Vincristine | 2002 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Neutropenia; Prednisolone; Prednisone; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2002 |
ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vincristine | 2002 |
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Vincristine | 2002 |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Failure | 2002 |
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukocyte Count; Lymphoma; Male; Mitoxantrone; Prednisolone; Prednisone; Recombinant Proteins; Time Factors; Treatment Outcome; Vincristine | 2003 |
A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisolone; Prednisone; Survival; Treatment Outcome; Vincristine | 2003 |
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Piperidines; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Quality of Life; Treatment Outcome | 2003 |
A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prognosis; Time Factors; Treatment Outcome; Vincristine | 2003 |
First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vincristine | 2003 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Regression Analysis; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Longevity; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Parents; Prednisolone; Prednisone; Prognosis; Survival Analysis; Vincristine | 2004 |
Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Mitoxantrone; Prednisone; Remission Induction; Salvage Therapy; Survival Analysis | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2004 |
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Approval; Drug Interactions; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; United States; United States Food and Drug Administration | 2004 |
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2005 |
[VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2005 |
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Risk Factors; Vidarabine; Vindesine | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2005 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Transplantation, Autologous | 2005 |
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncolo
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Transplantation, Autologous; Vincristine | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Pyruvaldehyde; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Genes, bcl-2; Humans; Lymphoma, Follicular; Methylprednisolone; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Prednisone; Procarbazine; Prospective Studies; Translocation, Genetic; Vincristine | 2005 |
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prednisone; Recombinant Proteins; Remission Induction; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Phosphatidylethanolamines; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Mitoxantrone; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2006 |
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome; Vincristine | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Comorbidity; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Pain; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2007 |
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fatal Outcome; Goserelin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Southwestern United States; Survival Analysis; Tosyl Compounds | 2008 |
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2008 |
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2008 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Infusions, Intravenous; Injections; Leukocyte Count; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Platelet Count; Prednisone; Survival Analysis | 2008 |
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Models, Statistical; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Genes, bcl-2; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Rituximab; Survival Analysis; Vidarabine; Vincristine | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2009 |
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recombinant Proteins; Treatment Outcome; Vincristine | 2009 |
Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Mitoxantrone; Nose Neoplasms; Paranasal Sinus Neoplasms; Prednisolone; Prednisone; Radioisotope Teletherapy; Radiotherapy, High-Energy; Treatment Outcome; Vincristine; Young Adult | 2010 |
Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anesthetics, Local; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Edetic Acid; Etoposide; Hepatitis, Alcoholic; Humans; Infusions, Intravenous; Male; Manganese; Metabolic Clearance Rate; Middle Aged; Mitoxantrone; Prednisone; Pyridoxal Phosphate; Vincristine; Young Adult | 2009 |
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Orchiectomy; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Dog Diseases; Dogs; Doxorubicin; Female; Lymphoma; Male; Mitoxantrone; Prednisone; Vincristine | 2010 |
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leucovorin; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Prednisolone; Prednisone; Proportional Hazards Models; Prospective Studies; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2011 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Neutropenia; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; HIV Infections; Humans; Male; Malnutrition; Mitoxantrone; Prednisone; Protease Inhibitors; Vincristine | 2010 |
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Disease-Free Survival; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Tubulin | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2011 |
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Humans; Interleukin-6; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Treatment Failure | 2012 |
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Exanthema; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Orchiectomy; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2012 |
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Male; Middle Aged; Mitoxantrone; Molecular Targeted Therapy; Orchiectomy; Prednisone; Prostatic Neoplasms; Proto-Oncogene Proteins c-met; Treatment Outcome | 2013 |
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine | 2013 |
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Rituximab; Stem Cell Transplantation; Survival Analysis; Vinblastine; Vinorelbine | 2013 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Models, Statistical; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Pain; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine | 2015 |
A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2015 |
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Monocytes; Prednisone; Prospective Studies; Rituximab; Survival Rate; Vidarabine; Vincristine | 2015 |
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2015 |
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Ramucirumab; Taxoids; Time Factors; Treatment Outcome; United States; Young Adult | 2015 |
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Etoposide; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Mitoxantrone; Prednisone; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides; Vincristine | 2015 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Neutrophils; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Severity of Illness Index; Taxoids; Time Factors; Treatment Outcome | 2016 |
Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxorubicin; Female; Lymphoma; Male; Mitoxantrone; Prednisone; Prospective Studies; Vincristine | 2016 |
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Glucocorticoids; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Outcome | 2018 |
Addition of mitoxantrone and prednisone to ADT.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prognosis; Prostatectomy; Prostatic Neoplasms; Survival Analysis; United States | 2018 |
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Topics: Aged; Analgesics; Anilides; Bone Neoplasms; Cancer Pain; Double-Blind Method; Drug Combinations; Humans; Male; Middle Aged; Mitoxantrone; Pain Management; Pain Measurement; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyridines | 2019 |
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2019 |
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Immunotherapy; Killer Cells, Natural; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Retrospective Studies; Rituximab; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2019 |
138 other study(ies) available for prednisone and mitoxantrone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone | 1992 |
[A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Prednisone; Procarbazine; Remission Induction; Vincristine | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Vincristine | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy; Texas; Vincristine | 1992 |
[The use of novantrone in combination with other preparations in hematosarcoma patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Time Factors; Vincristine | 1992 |
Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Macrophage Colony-Stimulating Factor; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Predictive Value of Tests; Prednisone; Remission Induction; Vindesine | 1992 |
[Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recurrence; Vincristine; Vindesine | 1992 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Vincristine | 1991 |
Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Evaluation; Drug Resistance; Female; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Survival Rate | 1990 |
NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Follow-Up Studies; Hematologic Diseases; Hodgkin Disease; Humans; Lymphocytes; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Remission Induction; Sperm Count; Vinblastine; Vincristine | 1990 |
Acute megakaryoblastic leukemia (FAB-M7) in an infant presenting with orbital chloroma and meningeal involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Exophthalmos; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Male; Meningeal Neoplasms; Mitoxantrone; Orbital Neoplasms; Prednisone; Thioguanine; Vincristine | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate | 1990 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisone; Prognosis; Prospective Studies; Recurrence; Regression Analysis; Retrospective Studies; Vincristine | 1987 |
[A comparative trial of C-novantrone OP(CNOP) vs C-adriamycin OP(CHOP) in the treatment of stage II-IV malignant lymphoma--the preliminary report].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Prednisone; Remission Induction; Vincristine | 1988 |
Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Mitoxantrone; Prednisone; Stroke Volume | 1988 |
Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Vincristine | 1988 |
Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; DNA Nucleotidylexotransferase; DNA Nucleotidyltransferases; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Liver; Male; Middle Aged; Mitoxantrone; Prednisone; Vincristine | 1987 |
[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Heart Failure; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Vincristine | 1984 |
[Cytostatic therapy in metastatic breast cancer].
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menopause; Methotrexate; Mitoxantrone; Prednisone; Vincristine | 1984 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1995 |
Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Life Tables; Lomustine; Male; Mechlorethamine; Mediastinal Neoplasms; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Remission Induction; Treatment Outcome; Vinblastine; Vincristine | 1994 |
Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Immunoproliferative Small Intestinal Disease; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Staging; Prednisone; Proportional Hazards Models; Retrospective Studies; Sex Ratio; Treatment Outcome; Turkey; Vincristine | 1994 |
Intrapleural bleomycin in the treatment of chylothorax.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chylothorax; Cyclophosphamide; Doxorubicin; Drug Administration Routes; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pleura; Prednisolone; Prednisone; Vincristine | 1994 |
Are alkylating agents a necessary component in the therapy of Hodgkin's disease.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Hodgkin Disease; Humans; Mitoxantrone; Prednisone; Survival Rate; Vinblastine; Vincristine | 1993 |
[Pleomorphic T-cell lymphoma. The diagnostic problems, therapeutic possibilities and infection-induced complications].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Humans; Interferon-alpha; Lymphoma, T-Cell, Peripheral; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Remission Induction; Time Factors; Vincristine | 1993 |
A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Cycle; Chromosome Aberrations; Female; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Sister Chromatid Exchange; Vinblastine; Vincristine | 1993 |
Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Vincristine | 1993 |
Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Graft Survival; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Mitoxantrone; Neutropenia; Prednisone; Thiotepa; Vincristine | 1993 |
Aggressive non-Hodgkin's lymphoma in elderly patients: where to go from here?
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Patient Selection; Prednisolone; Prednisone; Treatment Outcome; Vincristine | 1994 |
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.
Topics: Bone Marrow; Female; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Middle Aged; Mitoxantrone; Necrosis; Pain; Prednisone; Remission Induction; Tretinoin | 1994 |
Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans; Mechlorethamine; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Procarbazine; Vinblastine; Vincristine | 1994 |
The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Gallium; Hodgkin Disease; Humans; Lymphoid Tissue; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vinblastine; Vincristine | 1994 |
[Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Female; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Vincristine | 1993 |
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Ventricular Function, Left; Vincristine | 1993 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
One hundred thirteen men with hormone-refractory prostate cancer died today.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms | 1996 |
Therapy-related leukemia with a novel 21q22 rearrangement.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 21; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Polymerase Chain Reaction; Prednisolone; Prednisone; Procarbazine; Proto-Oncogene Proteins; Transcription Factors; Vincristine | 1996 |
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Vincristine | 1996 |
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation | 1996 |
Tracheoesophageal fistula developing during chemotherapy for non-Hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Prednisone; Tomography, X-Ray Computed; Tracheoesophageal Fistula; Vincristine | 1996 |
Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisone; Recombinant Proteins | 1996 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 1997 |
Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Life Tables; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Procarbazine; Prognosis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis; Vincristine | 1997 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Partial Thromboplastin Time; Plasminogen; Prednisone; Procarbazine; Protein C; Protein S; Thrombophilia; Time Factors; Vinblastine; Vincristine | 1997 |
A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.
Topics: Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Cosmids; Cyclophosphamide; DNA Probes; DNA Topoisomerases, Type II; Etoposide; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Middle Aged; Mitoxantrone; Prednisone; Topoisomerase II Inhibitors; Translocation, Genetic | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prednisone; Topoisomerase II Inhibitors; Vincristine | 1998 |
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
Topics: Adult; Anisocoria; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bleomycin; Brain Neoplasms; Cyclophosphamide; Cytarabine; Dizziness; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemiplegia; Humans; Lymphoma, Large-Cell, Anaplastic; Methotrexate; Mitoxantrone; Neoplastic Stem Cells; Nystagmus, Pathologic; Prednisone; Remission Induction; Thiamine; Vincristine; Vomiting; Wernicke Encephalopathy | 1999 |
High-grade non-Hodgkin's lymphoma treated in northern Norway--treatment, outcome, and prognostic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Norway; Prednisolone; Prednisone; Prognosis; Retrospective Studies; Treatment Outcome; Vincristine | 1999 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Vincristine | 1999 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Male; Mitoxantrone; Prednisone; Sperm Count; Spermatogenesis; Vinblastine; Vincristine | 2000 |
Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2000 |
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Leukapheresis; Lymphocyte Depletion; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pilot Projects; Polymerase Chain Reaction; Prednisone; Rituximab; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fatal Outcome; Follow-Up Studies; Gallium Radioisotopes; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methylprednisolone; Mitoxantrone; Neoplasm Recurrence, Local; Paclitaxel; Prednisone; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Stomach Neoplasms; Stomach Ulcer; Tomography, X-Ray Computed; Vincristine | 2001 |
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Netherlands; Prednisolone; Prednisone; Retrospective Studies; Survival Analysis; Vincristine | 2001 |
Incremental net benefit in randomized clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cost-Benefit Analysis; Defibrillators, Implantable; Heart Arrest; Humans; Male; Mitoxantrone; Models, Statistical; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, Replacement, Hip; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Femur Head Necrosis; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Treatment Outcome; Vincristine | 2001 |
Cost-effectiveness analysis with risk aversion.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Antineoplastic Agents; Bias; Cost-Benefit Analysis; Decision Making, Organizational; Evidence-Based Medicine; Fibrinolytic Agents; Health Planning; Health Services Research; Humans; Male; Mitoxantrone; Models, Econometric; Myocardial Infarction; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Risk Assessment; Technology Assessment, Biomedical | 2001 |
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Growth Substances; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Prednisolone; Prednisone; Reference Values; Retrospective Studies; Severity of Illness Index; Time Factors; Vincristine | 2001 |
T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Immunohistochemistry; Liver; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Prednisone; Retrospective Studies; Spleen; Survival Rate; T-Lymphocytes; Time Factors; Vincristine | 2001 |
CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prognosis; Survival Rate; Vincristine | 2002 |
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Humans; Hypopituitarism; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vincristine | 2002 |
Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Survival Analysis; Treatment Outcome | 2002 |
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Procarbazine; Prognosis; Survival Rate; Vincristine | 2003 |
Editorial: States and state transitions are all that really matter.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Mitoxantrone; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2002 |
NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21.
Topics: Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 21; Chromosomes, Human, X; Chromosomes, Human, Y; Diploidy; Hodgkin Disease; Humans; Male; Mitoxantrone; Mutagens; Neoplasm Staging; Phenotype; Prednisone; Spermatozoa; Time Factors; Vinblastine; Vincristine | 2003 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Orchiectomy; Prednisone; Recurrence; Remission Induction; Rituximab; Skin Neoplasms; Testis; Vincristine | 2003 |
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fever; Hospitalization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Prednisolone; Prednisone; Retrospective Studies; Risk Factors; Rituximab; Time Factors; Vincristine | 2003 |
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prednisone; Retrospective Studies; Vinblastine; Vincristine | 2004 |
Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, T-Cell; Male; Mitoxantrone; Nasal Cavity; Nose Neoplasms; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Salvage Therapy; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Immunomagnetic Separation; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Neoplastic Cells, Circulating; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured | 2004 |
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Retrospective Studies; Risk Factors; Rituximab; Treatment Outcome; United States; Vincristine | 2004 |
Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Cost-Benefit Analysis; Humans; Male; Markov Chains; Mitoxantrone; Models, Economic; Monte Carlo Method; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Radiotherapy; Sensitivity and Specificity | 2004 |
Multiple bilateral parotid sialoliths in a patient with mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) of the salivary glands.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Mitoxantrone; Parotid Diseases; Parotid Neoplasms; Prednisone; Salivary Gland Calculi; Sjogren's Syndrome; Stomach Neoplasms; Submandibular Gland; Ultrasonography; Vidarabine; Vincristine | 2005 |
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2005 |
Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Mitoxantrone; Neoplasm Staging; Omeprazole; Pantoprazole; Patient Compliance; Prednisone; Proton Pump Inhibitors; Rituximab; Stomach Neoplasms; Sulfoxides; Treatment Outcome; Vincristine | 2005 |
Doxetaxel: new indication. Prostate cancer: a few more weeks.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Taxoids; Time Factors | 2006 |
[Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carrier State; CD8-Positive T-Lymphocytes; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hepatitis B; HTLV-I Antibodies; Humans; Irinotecan; Lamivudine; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Pentostatin; Prednisone; Vincristine | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Middle Aged; Mitoxantrone; Prednisone; Urinary Bladder Neoplasms; Vincristine | 2006 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Radiotherapy Dosage; Recurrence; Remission Induction; Vincristine | 2007 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Mycobacterium tuberculosis; Prednisone; Retrospective Studies; Tuberculosis; Vincristine; Virus Activation | 2007 |
[Hodgkin lymphoma in Chile: experience of the national adult cancer program].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distribution; Chile; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; National Health Programs; Prednisolone; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Skin Neoplasms; Treatment Outcome; Vincristine | 2007 |
In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.
Topics: Animals; Antidepressive Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Binding, Competitive; Cell Line, Tumor; Cytarabine; Depression; Desensitization, Immunologic; Disease Models, Animal; Drug Administration Schedule; Drug Tolerance; Endocytosis; Humans; Lomustine; Male; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neuroblastoma; Oligopeptides; Phosphorylation; Prednisone; Receptors, Opioid, delta; Signal Transduction; Swimming | 2007 |
Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Failure; Treatment Outcome | 2007 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Meta-Analysis as Topic; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome | 2008 |
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vincristine | 2008 |
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Obesity; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Testosterone; Treatment Outcome | 2009 |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Germinal Center; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prognosis; Proportional Hazards Models; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2008 |
Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms | 2008 |
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; In Situ Hybridization, Fluorescence; Male; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neutropenia; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Splenic Rupture; Thiazoles; Vincristine; Young Adult | 2009 |
Clinical investigations in aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisolone; Prednisone; Rituximab; Vincristine | 2008 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Salvage Therapy; Vincristine; Vindesine; Young Adult | 2009 |
Hematology: germinal center or nongerminal center DLBCL?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center; Humans; Lymphoma, Large B-Cell, Diffuse; Mitoxantrone; Prednisolone; Prednisone; Prognosis; Vincristine | 2009 |
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Epothilones; Humans; Infusions, Subcutaneous; Male; Middle Aged; Military Personnel; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2009 |
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Interferon-alpha; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Retrospective Studies; Rituximab; Vidarabine; Vincristine | 2009 |
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Anxiety; Area Under Curve; Confidence Intervals; Data Collection; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Interviews as Topic; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Outcome Assessment, Health Care; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Psychometrics; Quality of Life; Self Concept | 2010 |
Cabazitaxel in prostate cancer: stretching a string.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Tissue Extracts | 2010 |
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Monitoring, Physiologic; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Time Factors; Vincristine; Young Adult | 2011 |
Cabazitaxel for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Stroke Volume; Taxoids; Treatment Failure; Treatment Outcome | 2011 |
Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisolone; Prednisone; Prognosis; Radiotherapy, Adjuvant; Registries; Retrospective Studies; Rituximab; Sweden; Treatment Outcome; Vincristine | 2012 |
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Interleukin-10; Interleukin-6; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Neoplasm Proteins; NF-kappa B p50 Subunit; Phenotype; Polymorphism, Single Nucleotide; Prednisone; Prognosis; Promoter Regions, Genetic; Rituximab; Sequence Deletion; Treatment Outcome; Vincristine; Young Adult | 2012 |
[Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Analysis of allele-specific expression in mouse liver by RNA-Seq: a comparison with Cis-eQTL identified using genetic linkage.
Topics: Alleles; Animals; Antineoplastic Combined Chemotherapy Protocols; Crosses, Genetic; Cyclophosphamide; Etoposide; Female; Gene Expression; Genetic Linkage; Genomic Imprinting; Liver; Male; Mice; Mice, Inbred C57BL; Mitoxantrone; Multigene Family; Polymorphism, Single Nucleotide; Prednisone; Quantitative Trait Loci; Sequence Analysis, RNA | 2013 |
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Failure; Vincristine | 2013 |
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Dexamethasone; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Remission Induction; Vincristine | 2014 |
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epothilones; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cladribine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Hashimoto Disease; Humans; Leukemia, Prolymphocytic, T-Cell; Leukocyte Count; Lymphatic Diseases; Mitoxantrone; Neck; Prednisone; Skin; Splenomegaly; Thyroid Gland; Thyroid Neoplasms; Tomography, X-Ray Computed; Vincristine | 2014 |
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2015 |
Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cluster Analysis; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; National Cancer Institute (U.S.); Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; United States | 2016 |
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Thalidomide | 2017 |
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Taxoids | 2017 |
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Rituximab; Vidarabine; Vincristine | 2018 |
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Humans; Lymphoma, B-Cell; Male; Mitoxantrone; Prednisone; Rituximab; Urinary Bladder; Urinary Bladder Neoplasms; Vincristine | 2018 |
Curing More Prostate Cancer: Thinking Through the Options.
Topics: Androgen Antagonists; Humans; Male; Mitoxantrone; Prednisone; Prostatectomy; Prostatic Neoplasms | 2018 |
Opposite Effects of the Spinach Food Matrix on Lutein Bioaccessibility and Intestinal Uptake Lead to Unchanged Bioavailability Compared to Pure Lutein.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Caco-2 Cells; Carotenoids; Cooking; Cyclophosphamide; Etoposide; Humans; Intestinal Absorption; Lutein; Male; Mitoxantrone; Postprandial Period; Prednisone; Spinacia oleracea; Swine; Swine, Miniature | 2018 |
Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Models, Biological; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2018 |
Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxorubicin; Female; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Retrospective Studies; Vincristine | 2019 |
Multimodality therapy for thymoma patients with pleural dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Humans; Induction Chemotherapy; Lomustine; Male; Middle Aged; Mitoxantrone; Myasthenia Gravis; Neoplasm Recurrence, Local; Pleural Diseases; Pneumonectomy; Prednisone; Retrospective Studies; Survival Rate; Thymoma; Thymus Neoplasms | 2019 |
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Topics: Activating Transcription Factor 3; Adenosine A1 Receptor Antagonists; Adult; Aged; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytarabine; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Mitoxantrone; Prednisone; Receptor, Adenosine A1; Tumor Escape; Xenograft Model Antitumor Assays | 2020 |
Coacervation in Cationic Polyelectrolyte Solutions with Anionic Amino Acid Surfactants.
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Cations; Cyclophosphamide; Etoposide; Hair Preparations; Hydrophobic and Hydrophilic Interactions; Mitoxantrone; Polyelectrolytes; Prednisone; Solutions; Static Electricity; Surface Properties; Surface Tension; Surface-Active Agents; Water; X-Ray Diffraction | 2020 |
An open protocol for evaluating the accuracy of guided implant surgery by using digital casts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Computer-Aided Design; Dental Implants; Etoposide; Mitoxantrone; Prednisone; Vincristine; Workflow | 2021 |
Meiotic susceptibility for induction of sperm with chromosomal aberrations in patients receiving combination chemotherapy for Hodgkin lymphoma.
Topics: Adult; Adult Germline Stem Cells; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Chemoradiotherapy; Chromosome Aberrations; Cohort Studies; Fertility Preservation; Hodgkin Disease; Humans; In Situ Hybridization, Fluorescence; Male; Meiosis; Mitoxantrone; Mutagenesis; Organ Sparing Treatments; Organs at Risk; Prednisone; Radiotherapy Dosage; Semen Analysis; Spermatogenesis; Spermatozoa; Testis; Time Factors; Vinblastine; Vincristine | 2020 |